#United States #Dover #Expert Systems #Mwyngil Therapeutics #GPR75 Modulators

Mwyngil Therapeutics Enters Licensing Agreement with Expert Systems Inc.

DOVER, Del., Nov. 6, 2025 — Mwyngil Therapeutics Inc. has announced a pivotal partnership with Expert Systems Inc. focusing on the in-licensing of lead GPR75 modulators and a proprietary cell-surface discovery platform. This collaboration aims to bolster Mwyngil’s capabilities in developing innovative small-molecule therapies targeting cardiovascular, metabolic, and inflammatory diseases.

Mwyngil, committed to pioneering first-in-class treatments, sees this venture as a significant stride in their approach toward addressing chronic diseases that heavily impact public health. Though the financial specifics of this licensing agreement remain undisclosed, the implications for both companies are profound.

Understanding GPR75

GPR75 is an orphan G-protein–coupled receptor that is primarily expressed in critical areas such as hypothalamic neurons, adipose tissue, liver, kidney, and vascular endothelium. Studies in human genetics have revealed that individuals possessing loss-of-function variants of GPR75 exhibit lower body mass indices and increased insulin sensitivity, thereby presenting a unique opportunity for intervention in obesity and type 2 diabetes (T2D) management.

The innovative GPR75 reverse agonists developed through this collaboration are engineered to suppress baseline receptor signaling, thus mimicking the protective benefits observed in these genetic variants. These small-molecule therapies could potentially offer a transformative approach to treating obesity and T2D effectively.

Enhancing Therapeutic Strategies

Tudor Oprea, MD, PhD, CEO of Expert Systems Inc., outlined the complementary nature of this partnership. The combination of GPR75 reverse agonists alongside Mwyngil’s systemic NLRP3 inhibitors represents a dual approach targeting the convergence of metabolism and inflammation. This synergistic mechanism is particularly critical considering the intertwined nature of metabolic diseases and chronic inflammation.

• - Metabolic Benefits: GPR75 reverse agonism can facilitate enhanced insulin sensitivity while regulating weight. Meanwhile, NLRP3 inhibition works to alleviate inflammation-driven insulin resistance, providing amplified glycemic control.
• - Inflammatory Control: The modulation of GPR75 can help in down-regulating triggers that provoke inflammasome activation. When paired with NLRP3 inhibitors that block inflammasome assembly, this strategy aims for extensive suppression of chronic inflammatory conditions.
• - Cardiovascular Health: Improvements in critical parameters such as blood pressure, endothelial function, and vascular inflammation could significantly reduce cardiovascular risks associated with metabolic disorders.
• - Kidney Health: GPR75 modulation presents a potential avenue for mitigating renal stress, while NLRP3 inhibition promises to alleviate tubular injury, thereby providing a comprehensive approach to kidney protection.

Promising Early Results

Preclinical trials of Mwyngil's newly acquired GPR75 reverse agonists have demonstrated:

• - Low-nanomolar potency and remarkable target selectivity in vitro.
• - Good oral bioavailability allowing for a convenient once-daily dosing schedule.
• - Favorable safety and tolerability profiles highlighted by significant reductions in relative weight gain in diet-induced obesity models, all while preserving lean body mass.

Mwyngil is dedicated to advancing these promising candidates and further developing related intellectual property within its existing cardiometabolic and chronic-inflammation frameworks.

About Mwyngil Therapeutics

Founded in Dover, Delaware, and Boston, Massachusetts, Mwyngil Therapeutics is a biopharmaceutical firm focused on creating groundbreaking therapies designed to penetrate the brain and tackle systemic inflammation effectively. With funding from notable investors such as Torrey Pines Investment and OrbiMed, Mwyngil is committed to ushering in novel solutions for significant health challenges. Recently, the company forged a partnership involving one of its NLRP3 inhibitors for potential applications in Parkinson's disease.

About Expert Systems Inc.

Expert Systems Inc. operates as a life-science accelerator, striving to advance precision therapeutics through an AI/ML-enabled platform. This comprehensive approach covers all facets, from drug design to clinical-ready opportunities, significantly shortening timelines and fostering innovation in the life sciences sector.

For further information, please visit Mwyngil.com and ExpertSystems.inc.